Omeros’ (OMER) Hold Rating Reaffirmed at Needham & Company LLC

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Thursday,Benzinga reports.

A number of other analysts have also recently weighed in on the stock. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. Finally, Rodman & Renshaw assumed coverage on Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

Omeros Price Performance

Shares of NASDAQ:OMER opened at $10.24 on Thursday. Omeros has a fifty-two week low of $2.61 and a fifty-two week high of $13.60. The business has a 50-day moving average of $6.96 and a two-hundred day moving average of $5.13. The stock has a market capitalization of $593.41 million, a P/E ratio of -4.43 and a beta of 1.97.

Hedge Funds Weigh In On Omeros

Several large investors have recently bought and sold shares of OMER. Geode Capital Management LLC grew its stake in Omeros by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock worth $5,318,000 after purchasing an additional 6,839 shares during the period. State Street Corp grew its holdings in Omeros by 0.3% during the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after purchasing an additional 3,839 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Omeros by 4.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock worth $1,926,000 after purchasing an additional 18,454 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Omeros by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after purchasing an additional 31,081 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Omeros by 6.1% in the second quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after acquiring an additional 6,435 shares during the period. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.